Procell Biologics was established in 2021 with the intent to be a hub for the development and manufacture of biologic products for the domestic and international markets. Our biosimilars address metabolic disorders, inflammatory diseases, and various types of cancer. We also have built capabilities for both biosimilar and biotherapeutic research. We envisage extending our services to CDMO activities by end-2024.